Biocryst Pharmaceuticals BCRX
NASDAQ BCRX
$8.32 +0.05 (+0.67%)
As of: Sep 30, 2026 · 3:56 PM EDT

Biocryst Pharmaceuticals (BCRX) Receivables - Other (2011 - 2013)

Updated

Biocryst Pharmaceuticals (BCRX) recorded Receivables - Other of $2.37 million in Q3 2013, down 37.1% from $3.77 million a year earlier but up 131.3% from the prior quarter.

Analysis

Biocryst Pharmaceuticals (BCRX) Receivables - Other (2011 - 2013) Analysis & Trends

At the end of FY2012, Biocryst Pharmaceuticals reported Receivables - Other of $4.56 million, down 21.8% from FY2011.

  • Across earlier years, Receivables - Other came in at $5.83 million in FY2011.
  • Quarterly Receivables - Other has ranged from $1.02 million in Q2 2013 to $5.83 million in Q4 2011 over the past five years.
  • Per Business Quant, the preceding three quarters came in at $1.02 million (Q2 2013), $4.33 million (Q1 2013) and $4.56 million (Q4 2012).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Biocryst Pharmaceuticals 2.11 Bn 1.03 Bn 214.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2013 2.37 Mn
Jun 30, 2013 1.02 Mn
Mar 31, 2013 4.33 Mn
Dec 31, 2012 4.56 Mn
Sep 30, 2012 3.77 Mn
Jun 30, 2012 5.08 Mn
Dec 31, 2011 5.83 Mn
API Access

Biocryst Pharmaceuticals Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=BCRX&period=max&api_key=YOUR_API_KEY